Samuel Dwight Lyons, MD in Kahului, HI - Surgery

Samuel Dwight Lyons, MD is a Surgery physician based in Kahului, Hawaii. Samuel Dwight Lyons is licensed to practice in Hawaii (license number MD6373) and his current practice location is 33 Lono Ave Ste 250, Kahului, Hawaii. He can be reached at his office (for appointments etc.) via phone at (808) 866-5335.

NPI number for Samuel Dwight Lyons is 1922021492 and his current mailing address is 33 Lono Ave Ste 250, Kahului, Hawaii. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1922021492.

Contact Information

	Samuel Dwight Lyons, MD
	33 Lono Ave Ste 250, Kahului, HI 96732
	(808) 866-5335
	(808) 866-5330

Physician's Profile

Full Name	Samuel Dwight Lyons
Gender	Male
Speciality	Surgery
Location	33 Lono Ave Ste 250, Kahului, Hawaii
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1922021492
Provider Enumeration Date: 07/25/2006
Last Update Date: 07/21/2022

Medical Identifiers

Medical identifiers for Samuel Dwight Lyons such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1922021492	NPI	-	NPPES
530243	Other	HI	UHA
B33874	Other	HI	HMSA - 65CP - HMSA QUEST
6373	Other	HI	TRICARE - CHAMPUS

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
208600000X	Surgery	MD6373 (Hawaii)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Samuel Dwight Lyons is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Samuel Dwight Lyons, MD 33 Lono Ave Ste 250, Kahului, HI 96732-1634 Ph: (808) 866-5335	Samuel Dwight Lyons, MD 33 Lono Ave Ste 250, Kahului, HI 96732 Ph: (808) 866-5335

News Archive

Proteostasis Therapeutics to use GeneGo's MetaCore integrated software

GeneGo, Inc., the leading systems biology tools company, announced today that Proteostasis Therapeutics has licensed its data mining and analysis platform, MetaCore. Proteostasis Therapeutics is the first company dedicated to the discovery of novel small molecule therapeutics based upon understanding the body's Proteostasis Network. The Proteostasis Network maintains the body's natural balance of proteins to protect us from numerous diseases.

FRC expresses disappointment over federal taxpayer funding of embryonic stem cell research

Family Research Council expressed disappointment in a 2-1 split decision today by the U.S. Court of Appeals in Washington, D.C. that allows the Obama administration to continue federal taxpayer funding of embryonic stem cell research.

Contrast agent for tumor diagnostics

X-rays are not the only way: visible and especially infrared light can also be used to image human tissue. The effectiveness of optical imaging processes can be significantly improved with suitable dyes used as contrast agents. In the journal Angewandte Chemie, a team led by Wenbin Lin at the University of North Carolina (Chapel Hill, USA) has now introduced a novel contrast agent that marks tumor cells in vitro. The dye is a phosphorescent ruthenium complex incorporated into nanoparticles of a metal–organic coordination polymer, which allows an extraordinarily high level of dye loading.

FDA Advisory Committee votes in favor of expanding pain indications for Eli Lilly's Cymbalta

The U.S. Food and Drug Administration (FDA) Anesthetic and Life Support Drugs Advisory Committee voted 8-6 in favor of expanding the pain indications for Eli Lilly and Company's (NYSE: LLY) Cymbalta® (duloxetine HCl) to a broader pain population that will be further defined by the FDA, if approved.

FUJIFILM enters definitive agreement to acquire Merck

FUJIFILM Corporation and Merck, known as MSD outside the United States and Canada, today announced they have entered into a definitive agreement by which Fujifilm will acquire the Merck BioManufacturing Network, a leading provider of contract manufacturing and development services for the biopharmaceutical industry and wholly owned by Merck.

Samuel Dwight Lyons, MD - Surgery in Kahului, HI